Chong Kun Dang has completed the sale transfer and takeover of 'Januvia (sitagliptin phosphate hydrate),' a diabetes drug that generates annual sales of KRW 23 billion in South Korea.

Conseqently, what was previously labelled as MSD's is now labelled as Chong Kun Dang's in South Korea.

According to industry sources on January 20, the pharmaceutical company label for three Januvia items (25 mg, 50 mg, 100 mg) registered in the National Health Insurance Service's reimbursement list will be changed from MSD Korea to Chong Kun Dang.

The change is due to adjustments following the sale transfer and takeover. The insurance authority allows the final ceiling price to be the same